editasmedicine.com - EDIT Company Value to Revenue

Public company logo of Editas Medicine Inc (EDIT)

Editas Medicine, Inc. (EDIT) is implementing robotic CRISPR platforms and AI to automate bio-screening, thereby eliminating human error. This enterprise value-to-revenue chart reflects the current market valuation of the business, where the metric stands at 2899.46. The company aims for leadership in DNA mutation correction by developing radical therapies. Meanwhile, its developments are shielded from export risks, maintaining a stable scientific and clinical environment.

EDIT editasmedicine.com: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Editas (EDIT)

- issuer market value details:
- money and cash flow information:
Fundamental company valuation:EDIT (editasmedicine.com)
Core merchandise of Editas Medicine Inc

This indicator determines the market value of the business, accounting for net debt per unit of generated revenue. The calculation combines market capitalization and liabilities, eliminating the influence of financing structure on the efficiency assessment. The price action of the EV/Sales multiple allows for the timely identification of asset accumulation phases. For Editas Medicine, Inc. (EDIT), such transparency is critical when implementing costly ESG standards. The greening of genome editing centers impacts capital expenditures, which is reflected in the final ratio.

Competitor analysis

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|Avidity (RNA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple CRSP|Total Company Value-to-Revenue Ratio GeneDx|Enterprise Value-to-Revenue Ratio Ultragenyx RARE|Total Company Value-to-Revenue Ratio Beam Therapeutics (BEAM)|SRPT: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Twist Bioscience|TXG (10x Genomics) - Company Value to Revenue|Intellia Therapeutics, Inc. (NTLA) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Stoke Therapeutics Inc|BLFS: Business Value to Revenue|Company Value to Revenue WVE (Wave Life Sciences Corp)|Total Company Value-to-Revenue Ratio Maze Therapeutics Corp|Sionna Therapeutics Inc - Company Value to Revenue|PRME (primemedicine.com) - Enterprise Value to Sales Volume|TSHA - Enterprise Value-to-Revenue Ratio|QURE (uniQure) - Company Value to Revenue Ratio|MeiraGTx Corp (MGTX) - Enterprise Value-to-Revenue Ratio|Regenxbio - Business Value to Revenue|Enterprise Value-to-Revenue Ratio solidbio.com|Enterprise Value-to-Revenue Multiple ocugen.com OCGN|EV/Sales Multiple PACB|Benitec - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Design Therapeutics DSGN|EV/Sales Multiple Rocket Pharmaceuticals RCKT|Enterprise Value to Sales Volume 4D Molecular Corp|LXEO: Enterprise Value-to-Revenue Ratio|KRRO (Korro Bio, Inc) - Company Value to Revenue|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple